| __timestamp | Corcept Therapeutics Incorporated | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 34916000 | 1499100000 |
| Thursday, January 1, 2015 | 36949000 | 1923500000 |
| Friday, January 1, 2016 | 45240000 | 2351400000 |
| Sunday, January 1, 2017 | 62416000 | 2564000000 |
| Monday, January 1, 2018 | 81289000 | 2397300000 |
| Tuesday, January 1, 2019 | 100359000 | 2503400000 |
| Wednesday, January 1, 2020 | 105326000 | 3344600000 |
| Friday, January 1, 2021 | 122356000 | 4529200000 |
| Saturday, January 1, 2022 | 152848000 | 4179100000 |
| Sunday, January 1, 2023 | 184259000 | 4650100000 |
Unlocking the unknown
In the ever-evolving pharmaceutical landscape, operational efficiency is key. Over the past decade, Viatris Inc. and Corcept Therapeutics Incorporated have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Viatris Inc. consistently reported higher SG&A expenses, peaking at approximately $4.65 billion in 2023, a staggering 210% increase from 2014. In contrast, Corcept Therapeutics, while smaller in scale, demonstrated a significant growth trajectory, with SG&A expenses rising by over 400% during the same period, reaching around $184 million in 2023. This comparison highlights Viatris's expansive operational scale versus Corcept's rapid growth strategy. As the industry continues to adapt to new challenges, understanding these financial dynamics offers valuable insights into corporate strategies and market positioning.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Viatris Inc.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Corcept Therapeutics Incorporated
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Viatris Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Blueprint Medicines Corporation
Who Optimizes SG&A Costs Better? Viatris Inc. or CymaBay Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Viatris Inc. or Amneal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Viatris Inc. vs ACADIA Pharmaceuticals Inc. Trends and Insights
Comparing SG&A Expenses: Viatris Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Viatris Inc. vs Veracyte, Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Galapagos NV
Who Optimizes SG&A Costs Better? Corcept Therapeutics Incorporated or Catalyst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Corcept Therapeutics Incorporated vs PTC Therapeutics, Inc.